TEMOVATE E Drug Patent Profile
✉ Email this page to a colleague
When do Temovate E patents expire, and when can generic versions of Temovate E launch?
Temovate E is a drug marketed by Fougera Pharms and is included in one NDA.
The generic ingredient in TEMOVATE E is clobetasol propionate. There are fourteen drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the clobetasol propionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Temovate E
A generic version of TEMOVATE E was approved as clobetasol propionate by COSETTE on February 16th, 1994.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TEMOVATE E?
- What are the global sales for TEMOVATE E?
- What is Average Wholesale Price for TEMOVATE E?
Summary for TEMOVATE E
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 80 |
| Clinical Trials: | 2 |
| Patent Applications: | 4,476 |
| DailyMed Link: | TEMOVATE E at DailyMed |
Recent Clinical Trials for TEMOVATE E
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| VA Office of Research and Development | N/A |
| University Hospitals Cleveland Medical Center | N/A |
| GlaxoSmithKline | Phase 2 |
US Patents and Regulatory Information for TEMOVATE E
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fougera Pharms | TEMOVATE E | clobetasol propionate | CREAM;TOPICAL | 020340-001 | Jun 17, 1994 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
